Yonhap Infomax NewsLotte Biologics CEO James Park announced at BioJapan that the company aims to establish long-term partnerships with over 10 Japanese pharmaceutical firms, leveraging the Lotte brand and expanding its ADC CDMO business, while considering further investment in its U.S. Syracuse facility.
#YonhapInfomax
#LotteBiologics #JamesPark #BioJapan #ADC #CDMO
#Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=84991
#YonhapInfomax
#LotteBiologics #JamesPark #BioJapan #ADC #CDMO
#Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=84991
James Park, CEO of Lotte Biologics – Aims to Establish Long-Term Partnerships with Japanese Pharmaceutical Companies
Lotte Biologics CEO James Park announced at BioJapan that the company aims to establish long-term partnerships with over 10 Japanese pharmaceutical firms, leveraging the Lotte brand and expanding its ADC CDMO business, while considering further investment in its U.S. Syracuse facility.